Page tree
Skip to end of metadata
Go to start of metadata


This is a phase II study in patients at least 18 years of age to determine the safety and effectiveness of TRC105 as a treatment for metastatic urothelial cancer that has not responded to standard treatments. Participants will continue to take TRC105 for as long as the treatment is effective against the cancer and as long as the side effects are not severe enough to stop treatment. Outcome measures include safety, toxicity, and progression-free survival.




Principal Investigator:

Andrea Apolo

  • No labels